Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Clinical trial NCT00729742 · COMPLETED

Trial details

NCT number: NCT00729742
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Non-small Cell Lung

Start date: 2009-02-01
Primary completion: 2010-06-01
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.